埃克替尼治疗非小细胞肺癌脑转移的临床疗效观察

洪乔军; 罗晶晶; 方瑜; 孙成龙; 程先平; 周道平

doi:10.13898/j.cnki.issn.1000-2200.2018.09.006

埃克替尼治疗非小细胞肺癌脑转移的临床疗效观察

1. 安徽省第二人民医院肿瘤科, 安徽合肥 230041;
2. 安徽省第二人民医院放疗科, 安徽合肥 230041

基金项目:

安徽省高等学校自然科学研究重点项目（KJ2018A0813）

详细信息

作者简介:
洪乔军(1983-),男,主治医师.

中图分类号: R734.2
计量
- 文章访问数: 4347
- HTML全文浏览量: 844
- PDF下载量: 35
出版历程
- 收稿日期: 2018-03-15
- 修回日期: 2018-08-04

Clinical observation of icotinib in the treatment of advanced non-small cell lung cancer with brain metastases

1. Department of Oncology, Anhui No.2 Provincial People's Hospital, Hefei Anhui 230041, China;
2. Department of Radiotherapy, Anhui No.2 Provincial People's Hospital, Hefei Anhui 230041, China

摘要

摘要: 目的：分析埃克替尼治疗非小细胞肺癌（NSCLC）脑转移的疗效和安全性。方法：对26例NSCLC脑转移病人的临床资料进行回顾性分析。所有病人均服用埃克替尼125mg，每天3次，直至病情进展、死亡或出现不可耐受的不良反应。结果：26例病人颅内病变有效率（ORR）和疾病控制率（DCR）分别为7.7%和84.6%，全身病变ORR和DCR分别为11.5%和76.9%。总体DCR与病人的年龄、性别、吸烟状况、PS评分、病理类型、表皮生长因子受体（EGFR）突变状态、埃克替尼治疗时机、脑转移灶数目（单发或多发）、脑部放疗及化疗与否等临床特征均未见相关性（P>0.05）。全组中位无进展生存时间（PFS）和中位生存时间（OS）分别为4.0个月（95%CI 2.4~5.6个月）和8.3个月（95%CI 4.9~11.7个月）。PFS与病人体力活动状态（PS）评分、EGFR突变状态具有相关性（P<0.01和P<0.05），OS与病人的年龄、PS评分、病理类型、EGFR状态、化疗与否具有相关性（P<0.05~P<0.01）。不良反应可耐受，主要表现为轻度皮疹、腹泻等。结论：埃克替尼治疗NSCLC脑转移具有一定疗效，且安全性好，可作为脑转移病人个体化治疗策略之一。
- 非小细胞肺癌 /
- 脑转移 /
- 埃克替尼
Abstract: Objective:To analyze of the efficacy and safety of icotinib in the treatment of brain metastases from non-small cell lung cancer(NSCLC).Methods:The clinical data of 26 NSCLC patients with brain metastases treated with icotinib were reviewed retrospectively.All patients were treated with icotinib (125 mg,3 times a day) until disease progression,death or unacceptable toxicities.Results:In terms of intracranial lesions,the objective response rate(ORR) and disease control rate(DCR) were 7.7% and 84.6%.As for systemic disease,ORR and DCR were 11.5% and 76.9%,respectively.Total DCR was not related to age,sex,smoking status,pathological type,PS score,epidermal growth factor receptor(EGFR) mutation,the timing of icotinib treatment,the number of brain metastases (single or multiple) and brain radiotherapy and chemotherapy or not(P>0.05).The median progression-free survival(PFS) and median overall survival(OS) were 4 months (95%CI 2.4-5.6 months) and 8.3 months(95%CI 4.9-11.7 months),respectively.PFS was related to PS score and the mutation of EGFR in patients (P<0.01 and P<0.05)).OS was related to age,PS score,pathological type,EGFR status,and chemotherapy(P<0.05 to P<0.01).The side effects were tolerable,which were mainly mild rash and diarrhea.Conclusions:Icotinib may be effective on brain metastasis in NSCLC patients,and the toxicities are tolerable,which can be used as new treatment option for NSCLC patients with brain metastases.
- non-small cell lung cancer /
- brain metastases /
- icotinib

HTML全文

参考文献(15)

[1]	LOGANADANE G,HENDRIKS L,LE PÉCHOUX C,et al.The current role of whole brain radiation therapy in non-small cell lung cancer patients[J].J Thorac Oncol,2017,12(10):1467.
[2]	KONG LL,WANG LL,XING LG,et al.Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases[J].Chronic Dis Transl Med,2017,3(4):221.
[3]	李莎,吴静,胡亚辉,等.Ⅳ期肺腺癌初诊时转移特征和生存分析[J].郑州大学学报(医学版),2017,52(4):443.
[4]	杨晓娇,高俊珍.肺癌患者循环肿瘤DNA中EGFR-T790M突变检测TKI获得性耐药[J].国际呼吸杂志,2018,19(4):297.
[5]	杨燕,周争光,李玉梅,等.肺癌中血清乳酸脱氢酶和超氧化物歧化酶联合检测的意义[J].蚌埠医学院学报,2017,42(6):716.
[6]	石雁,葛路路,王静,等.FOXC1在非小细胞肺癌组织中的表达及与预后的关系[J].郑州大学学报(医学版),2018,53(2):209.
[7]	SHEPHERD FA,RODRIGUES PJ,CIULEANU T,et al.Erlotinib in previously treated non-small-cell lung cancer[J].N Engl J Med,2005,353(2):123.
[8]	MOK TS,WU YL,THONGPRASERT S,et al.Geitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2011,361(10):947.
[9]	TAN F,SHEN X,WANG D,et al.Icotinib (BPI-2009H),a novel EGFR tyrosine kinase inhibitor,displays potent eficacy in preclinical studies[J].Lung Cancer,2012,76(2):177.
[10]	WU YL,ZHOU C,CHENG Y,et al.Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases:a phase Ⅱ study (CTONG-0803) [J].Ann Oncol,2013,24(4):993.
[11]	IUCHI T,SHINGYOJI M,SAKAIDA T,et al.Phase Ⅱ trial of gef itinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma[J].Lung Cancer,2013,82(2):282.
[12]	SHI Y,ZHANG L,LIU X et al.Icotinib versus geitinib in previously treated advanced non-small cell lung cancer(ICOGEN):a randomised,double-blind phase 3 non-inferiority trial[J].Lancet Oncol,2013,14(10):953.
[13]	YANG JJ,ZHOU C,HUANG Y,et al.Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases(BRAIN):a multicentre,phase 3,open-label,parallel,randomised controlled trial[J].Lancet Respir Med,2017,5(9):707.
[14]	FAN Y,HUANG Z,FANG L,et al.A phase Ⅱ study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer[J].Cancer Chemother Pharmacol,2015,76(3):517.
[15]	KEPKA L，CIESLAK E，BUJKO K，et al.Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer:the RTOG RPA intra-classe sanalysis[J].Acta Oncol，2005,44(4):389.

施引文献(3)

期刊类型引用(3)

1.	刘瑛，黄念，李秋波. 奥西替尼对比埃克替尼一线治疗EGFR突变转移性非小细胞肺癌的临床效果. 吉林医学. 2023(10): 2843-2847 . 百度学术
2.	黄卫彬，刘羽，洪琳. 盐酸埃克替尼片联合全脑放疗治疗非小细胞肺癌脑转移的临床效果分析. 中国处方药. 2021(01): 119-120 . 百度学术
3.	王超. 埃克替尼联合放疗治疗非小细胞肺癌脑转移的临床效果分析. 临床研究. 2020(08): 88-89 . 百度学术